Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Am J Kidney Dis. 2021 May 14;78(3):418–428. doi: 10.1053/j.ajkd.2021.02.339

Box 1.

Future Research

 • Benefits of early (eGFR >20 ml/min/1.73 m2) SPK transplant in patients with impaired kidney function and rapidly progressive diabetic complications and/or problematic hypo- and hyperglycemia despite advanced automated insulin delivery system.
 • Patient survival and micro- and macro-vascular diabetic complications in PAK recipients as compared to KTA on an advanced automated insulin delivery systems.
 • Kidney allograft survival in PAK recipients as compared to KTA on advanced automated insulin delivery systems.
 • Outcomes of pancreas versus islet transplantation in patients with C-peptide positive diabetes; appropriate selection of candidates for degrees of insulin resistance.
 • Assessment of pancreas insulin secretory reserve in patients with type 2 diabetes and advanced chronic kidney disease.
 • Preservation of renal function in PTA/ITA recipients with diabetic kidney disease.
 • Surgical pancreas transplant related morbidity and long-term outcomes in high risk recipients-e.g. age >55 years, frailty or significant physical impairment, advanced cardiovascular and peripheral vascular disease, etc.
 • Pancreas allograft outcomes in SPK recipients as compared to the solitary pancreas transplant in terms of alloimmune rejection, autoimmune recurrence, and graft survival.
 • Long-term risk of sensitization with islet transplantation in IAK recipients.
 • The impact of CMV disease and its prevention on pancreas and islet transplant outcomes.
 • Organ donor allocation for pancreas versus islet transplantation.
 • Randomized studies evaluating efficacy of less nephrotoxic and diabetogenic immunosuppression.
 • The impact of recipient prehabilitation strategies on long term outcomes.
 • Organ preservation strategies to reduce ischemia reperfusion injury and optimize isolated islet yields and function.
 • Comparison of patients reported outcomes between SPK, SIK and KTA recipients, as well as between PAK, IAK and KTA recipeints.

eGFR – estimated Glomerular Filtration Rate; IAK- islet after kidney; ITA – Islet Transplant Alone; KTA-kidney transplant alone, PAK – Pancreas after kidney; PTA – Pancreas Transplant Alone; SPK – Simultaneous Pancreas-Kidney.